BRPI0606768A2 - forma de dosagem oral compreendendo rosiglitazona - Google Patents

forma de dosagem oral compreendendo rosiglitazona

Info

Publication number
BRPI0606768A2
BRPI0606768A2 BRPI0606768-9A BRPI0606768A BRPI0606768A2 BR PI0606768 A2 BRPI0606768 A2 BR PI0606768A2 BR PI0606768 A BRPI0606768 A BR PI0606768A BR PI0606768 A2 BRPI0606768 A2 BR PI0606768A2
Authority
BR
Brazil
Prior art keywords
dosage form
composition
oral dosage
rosiglitazone
pellets
Prior art date
Application number
BRPI0606768-9A
Other languages
English (en)
Inventor
Vincenzo Re
Original Assignee
Sb Pharmco Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sb Pharmco Inc filed Critical Sb Pharmco Inc
Publication of BRPI0606768A2 publication Critical patent/BRPI0606768A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

FORMA DE DOSAGEM ORAL COMPREENDENDO ROSIGLITAZONA. Uma forma de dosagem oral compreendendo pelotas de uma primeira composição e pelotas de uma segunda composição, cada composição compreendendo 5-[4-[2-(N-metil-N-(2 piri-dil)amino)etóxi]benzil]tiazolidina-2,4-diona ou um sal ou solvato farmaceuticamente aceitável deste e um veículo farmaceuticamente aceitável para este, em que a primeira e a segunda composição são organizadas para liberar droga em taxas de liberação diferentes na administração, de preferência tal que a taxa de liberação da droga a partir da forma de dosagem seja consideravelmente independente de pH; um processo para preparar tal forma de dosagem e o uso de tal forma de dosagem na medicina.
BRPI0606768-9A 2005-02-07 2006-02-03 forma de dosagem oral compreendendo rosiglitazona BRPI0606768A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0502479.9A GB0502479D0 (en) 2005-02-07 2005-02-07 Novel compositions
PCT/EP2006/000999 WO2006082089A1 (en) 2005-02-07 2006-02-03 Oral dosage form comprising rosiglitazone

Publications (1)

Publication Number Publication Date
BRPI0606768A2 true BRPI0606768A2 (pt) 2009-07-14

Family

ID=34355902

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0606768-9A BRPI0606768A2 (pt) 2005-02-07 2006-02-03 forma de dosagem oral compreendendo rosiglitazona

Country Status (16)

Country Link
US (1) US20080139624A1 (pt)
EP (1) EP1845977A1 (pt)
JP (1) JP2008529984A (pt)
KR (1) KR20070104392A (pt)
CN (1) CN101155585A (pt)
AU (1) AU2006210135A1 (pt)
BR (1) BRPI0606768A2 (pt)
CA (1) CA2595409A1 (pt)
EA (1) EA200701680A1 (pt)
GB (1) GB0502479D0 (pt)
IL (1) IL184787A0 (pt)
MA (1) MA29280B1 (pt)
MX (1) MX2007009493A (pt)
NO (1) NO20074514L (pt)
TW (1) TW200640455A (pt)
WO (1) WO2006082089A1 (pt)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0203296D0 (en) * 2002-02-12 2002-03-27 Glaxo Group Ltd Novel composition
US8637512B2 (en) * 2002-07-29 2014-01-28 Glaxo Group Limited Formulations and method of treatment
EP2114404A4 (en) * 2006-12-21 2010-03-03 Alphapharm Pty Ltd COMPOUND AND PHARMACEUTICAL COMPOSITION
TWI441658B (zh) 2008-03-11 2014-06-21 Takeda Pharmaceutical 口腔崩解固體製劑
US20100068254A1 (en) * 2008-09-16 2010-03-18 Mahalaxmi Gita Bangera Modifying a medicament availability state of a final dosage form
US20100068233A1 (en) * 2008-09-16 2010-03-18 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Modifiable dosage form
US20100068275A1 (en) * 2008-09-16 2010-03-18 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Personalizable dosage form
US20100069821A1 (en) * 2008-09-16 2010-03-18 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Ex vivo modifiable medicament release-sites final dosage form
US20100068235A1 (en) * 2008-09-16 2010-03-18 Searete LLC, a limited liability corporation of Deleware Individualizable dosage form
US20100068278A1 (en) * 2008-09-16 2010-03-18 Searete Llc, A Limited Liablity Corporation Of The State Of Delaware Ex vivo modifiable medicament release-associations
US20100069887A1 (en) * 2008-09-16 2010-03-18 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Multiple chamber ex vivo adjustable-release final dosage form
CN109481419B (zh) * 2019-01-16 2021-04-02 中国人民解放军陆军军医大学第一附属医院 一种罗格列酮纳米制剂及其制备方法和用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030187074A1 (en) * 2002-03-04 2003-10-02 Javed Hussain Oral compositions for treatment of diabetes
US7985422B2 (en) * 2002-08-05 2011-07-26 Torrent Pharmaceuticals Limited Dosage form
CA2529984C (en) * 2003-06-26 2012-09-25 Isa Odidi Oral multi-functional pharmaceutical capsule preparations of proton pump inhibitors
UY28457A1 (es) * 2003-08-07 2005-03-31 Sb Pharmco Inc Nueva composición
WO2005065654A2 (en) * 2003-12-31 2005-07-21 Alpharma, Inc. Rosiglitazone formulations

Also Published As

Publication number Publication date
GB0502479D0 (en) 2005-03-16
MA29280B1 (fr) 2008-02-01
AU2006210135A1 (en) 2006-08-10
JP2008529984A (ja) 2008-08-07
EA200701680A1 (ru) 2007-12-28
KR20070104392A (ko) 2007-10-25
CA2595409A1 (en) 2006-08-10
IL184787A0 (en) 2007-12-03
CN101155585A (zh) 2008-04-02
EP1845977A1 (en) 2007-10-24
MX2007009493A (es) 2007-09-19
WO2006082089A1 (en) 2006-08-10
US20080139624A1 (en) 2008-06-12
NO20074514L (no) 2007-09-05
TW200640455A (en) 2006-12-01

Similar Documents

Publication Publication Date Title
BRPI0606768A2 (pt) forma de dosagem oral compreendendo rosiglitazona
BRPI0607803A2 (pt) forma de dosagem oral compreendendo rosiglitazona
AP1545A (en) Hydrochloride salts of 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione.
MY135973A (en) Modified release compositions comprising 5-[4-[2-(n-methyl-n-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2, 4-dione, optionally in the form of pharmaceutically acceptable derivative
AR045330A1 (es) Forma de dosificacion oral, procedimiento para su preparacion y uso del compuesto 5-(4-(2-(n-metil-n- (2-piridil)amino)etoxi )bencil) tiazolidin-2,4-diona o una sal o solvato farmaceuticamente aceptable del mismo para prepararla
CY1105354T1 (el) Ένα παραγωγο θειαζολιδινοδιονης και η χρηση του σαν αντι-διαβητικο
AP1715A (en) The hydrochloride salt of 5-[ 4 -[2 -(n-methyl-n- (2-pyridyl) amino) ethoxy]benzyl]thiazolidine -2,4-dione
DK1446404T3 (da) Rosiglitazonedisylater og deres anvendelse som antidiabetika
BRPI0607804A2 (pt) braçadeira de lámina despeladora com ranhuras de saìda de gordura
BR0112981A (pt) Sais tartarato de derivado de tiazolidinadiona
BR0112982A (pt) Sal tartarato de derivado de tiazolidinadiona
BR0112984A (pt) Sais tartarato de derivado de tiazolidinodiona
CY1107421T1 (el) Τρυγικα αλατα παραγωγου θειαζολιδινοδιονης
BR0111536A (pt) Sal de tiazolidinediona para tratamento de diabetes mellitus
AP1738A (en) Sodium salts of 5-[4-[2-(N-Methyl -N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione.
AP2002002684A0 (en) 5-(4-(2-(n-methyl-n-(2- pyridyl) amino)ethoxy) benzyl) thiazolidine-2, 4-dione hydriodide as pharmaceutical.5-(4-(2-(n-methyl-n-(2- pyridyl) amino)ethoxy) benzyl) thiazolidine-2, 4-dione hydriodide as pharmaceutical.5-(4-(2-(n-methyl-n-(2- pyridyl) amino)ethoxy) benzyl) thiazolidine-2, 4-dione hydriodide as pharmaceutical.5-(4-(2-(n-methyl-n-(2-pyridyl) amino) ethoxy)benzyl) thiazolidine-2,4-dione hydriodide as pharmaceutical
EP1867343A3 (en) Inclusion complexes of a cyclodextrin with a thiazolidine-2,4-dione
RS50130B (sr) Farmaceutska kompozicija 5-(4-(2-(n-metil-n-(2-piridil)amino)etoksi)benzil) tiazolidin-2,4-diona
CY1106397T1 (el) Βενζολοσουλφονικη 5-(4-(2-(ν-μεθυλο-ν-(2-πυριδιλ)αμινο)αιθοξυ)βενζυλο) θειαζολιδινο-2,4-διονη ˙ διepγασια παρασκευης αυτης ˙ πολυμορφες ι,ιι και ιιι αυτης ˙ και χρηση αυτης ως φαρμακευτικο δραστικο συστατικο
ECSP003434A (es) Nuevos compuestos
TH85149B (th) รูปแบบของการให้ยาทางปากซึ่งประกอบด้วย 5-[4-[2-(n-เมธิล-n-(2-ไพริดิล)อะมิโน)เอธอกซี]เบนซิล]ไธอะโซลิดีน-2,4-ไดโอน
TH84984B (th) รูปแบบของการให้ยาทางปากซึ่งประกอบด้วย5-[4-[2-(n-เมธิล-n-(2-ไพริดิล)อะมิโน)เอธอกซี]เบนซิล]ไธอะโซลิดีน-2,4-ไดโอน
TH85149A (th) รูปแบบของการให้ยาทางปากซึ่งประกอบด้วย 5-[4-[2-(n-เมธิล-n-(2-ไพริดิล)อะมิโน)เอธอกซี]เบนซิล]ไธอะโซลิดีน-2,4-ไดโอน

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: SMITHKLINE BEECHAM (CORK) LIMITED (IE)

Free format text: TRANSFERIDO DE: SB PHARMCO PUERTO RICO INC.

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2161 DE 05/06/2012.